U.S. markets open in 5 hours 9 minutes

Conformis, Inc. (CFMS)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
0.8972-0.0011 (-0.12%)
At close: 4:00PM EDT

0.8907 -0.01 (-0.72%)
Pre-Market: 4:12AM EDT

Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Price Crosses Moving Average

Price Crosses Moving Average

Previous Close0.8983
Open0.8907
Bid0.0000 x 800
Ask0.0000 x 1000
Day's Range0.8833 - 0.9254
52 Week Range0.6020 - 1.4900
Volume1,635,367
Avg. Volume5,742,727
Market Cap163.81M
Beta (5Y Monthly)1.26
PE Ratio (TTM)N/A
EPS (TTM)-0.3400
Earnings DateMay 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Overvalued
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021
    GlobeNewswire

    Conformis, Inc. to Release First Quarter 2021 Financial Results on May 5, 2021

    BILLERICA, Mass., April 07, 2021 (GLOBE NEWSWIRE) -- Conformis, Inc. (NASDAQ: CFMS) announced today that it will release its financial results for the first quarter ended March 31, 2021 after the market closes on May 5, 2021 at approximately 4:00 p.m. Eastern Time. Mark Augusti, CEO, and Bob Howe, CFO, will host a webcast and conference call also on Wednesday, May 5, 2021, at 4:30 p.m. Eastern Time to discuss the financial results and to provide a business update. The webcast will be live at: https://edge.media-server.com/mmc/p/vnzdh2h9. To attend by telephone, please use the information below for dial-in access. When prompted on dial-in, please utilize conference ID: 8727027.Participant conference numbers (877) 809-6331 (U.S./Canada) and (615) 247-0224 (International).Please dial in at least 10 minutes before the call to ensure timely participation. Please visit the Investor Relations website at ir.conformis.com on May 5, 2021 to view the earnings release prior to the webcast and conference call. The online archive of the webcast will be available on the company’s website at ir.conformis.com for 30 days. About Conformis, Inc. Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture, and sell joint replacement implants and instruments that are individually sized and shaped, which we refer to as personalized, individualized, or sometimes as customized, to fit each patient's unique anatomy. Conformis offers a broad line of sterile, personalized knee and hip implants and single-use instruments delivered to hospitals and ambulatory surgical centers. In clinical studies, the Conformis iTotal CR knee replacement system demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses issued patents and pending patent applications that cover personalized implants and patient-specific instrumentation for all major joints. For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/. CONTACT: Contact Investor Contact: Investor Relations ir@conformis.com (781) 374-5598

  • Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System
    Zacks

    Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System

    Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.

  • Varian Medical (VAR) Hits 52-Week High: What's Driving It?
    Zacks

    Varian Medical (VAR) Hits 52-Week High: What's Driving It?

    Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.